Zydus Lifesciences Reports Rs 6,573.7 Cr Revenue in Q1 FY26, Net Profit Rises 3%

US formulations, the company’s largest contributor at 49% of revenues, grew 3% YoY to Rs 31,817 million, supported by three new product launches and six ANDA approvals, including two tentative. International markets formulations surged 37% YoY to Rs 7,265 million, while APIs registered an 11% YoY rise to Rs 1,575 million.

On the innovation front, the company initiated Phase II(b) clinical trials of Usnoflast, a novel oral NLRP3 inflammasome inhibitor for amyotrophic lateral sclerosis (ALS), which has received USFDA Fast Track and Orphan Drug Designations. It also secured DCGI marketing authorisations for Rituximab and Aflibercept biosimilars and commenced Phase III trials for a second antibody drug conjugate.

Operationally, Zydus received USFDA Establishment Inspection Reports for its Ankleshwar and Dabhasa API facilities. In the vaccines portfolio, Phase II trials for the Hepatitis E vaccine were completed, and Phase IV trials for rabies vaccine have been initiated.

Commenting on the results, Dr Sharvil Patel, Managing Director, said, “Our Q1 FY2026 performance reflects disciplined execution, with most key businesses meeting expectations. We remain firmly on track to achieve our FY2026 aspirations while upholding the highest compliance standards.”